The DOI matches its Crossref record.
Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Abstract
Although surgical resection is the standard curative therapy for gastric cancer, these tumors are often diagnosed at an advanced stage, when surgery is not recommended. Alternative treatments such as radiotherapy and chemotherapy achieve only very modest results. There is therefore an urgent need to advance in this field of oncologic gastroenterology. The poor response of gastric cancer to chemotherapy is usually due to a combination of mechanisms of chemoresistance (MOC), which may include a reduction in drug uptake (MOC-1a), enhanced drug efflux (MOC-1b), a reduced proportion of active agents in tumor cells due to a reduction in pro-drug activation or an enhancement in drug inactivation (MOC-2), changes in the expression/function of the molecular targets of anticancer drugs (MOC-3), an enhanced ability of cancer cells to repair anticancer drug-induced DNA damage (MOC-4), and decreased expression/function of pro-apoptotic factors or up-regulation of anti-apoptotic genes (MOC-5). Two major goals of modern pharmacology aimed at overcoming this situation are the prediction of a lack of response to chemotherapy and the identification of the underlying mechanisms accounting for primary or acquired refractoriness to anticancer drugs. These are important issues if we are to select the best pharmacological regime for each patient and develop novel strategies to overcome chemoresistance. The present review reports updated information regarding the mechanisms of chemoresistance (from MOC-1 to MOC-5) in gastric cancer, the advances made in the prediction of the failure of chemotherapeutic treatment, and novel strategies based on gene therapy currently being developed to treat these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer
Jiang, M., Qi, L., Li, L., & Li, Y. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00349-0 · Cited by 686
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer
Zhai, J., Shen, J., Xie, G., Wu, J., He, M., Gao, L., Zhang, Y., Yao, X., & Shen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.002 · Cited by 272
Wang, X., Zhang, H., Bai, M., Ning, T., Ge, S., Deng, T., Liu, R., Zhang, L., Ying, G., & Ba, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.001 · Cited by 192
Metadata
- Authors
- Marin, J. J. G., Al-Abdulla, R., Lozano, E., Briz, O., Bujanda, L., M. Banales, J., & Macias, R. I. R.
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-02-10
- Volume
- 16
- Issue
- 3
- Pages
- 318-334
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2133176268
- Cited by
- 170
- References
- 0
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Resistance to Chemotherapy in Gastric Cancer. https://app.cochat.ai/papers/10.2174/1871520615666150803125121
- The paper
- Marin, J. J. G., Al-Abdulla, R., Lozano, E., Briz, O., Bujanda, L., M. Banales, J., & Macias, R. I. R. (2016). Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry. https://doi.org/10.2174/1871520615666150803125121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.